Differential Requirements for Activation of Integrated and Transiently Transfected Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat

AUTOR(ES)

Okada, Masahiko

FONTE

American Society for Microbiology

RESUMO

Adult T-cell leukemia (ATL) cells contain integrated human T-cell leukemia virus type 1 (HTLV-1) proviruses. Although the exact sequence of events leading to the development of ATL remains incompletely resolved, expression of the integrated HTLV-1 long terminal repeat (LTR) is likely required at some point during the process of T-cell transformation. While much has been learned about the regulated expression of transiently transfected LTR reporter plasmids, an analysis of factors required for expression of chromosomally integrated HTLV-1 LTR has not been done. Here, we have constructed CHOK1 and HeLa cells that contain an integrated HTLV-1 LTR-luciferase gene. Using these cells, we have compared the requirements for activation of transiently transfected versus stably integrated HTLV-1 LTR. We observed different requirements for CREB, p300, and P/CAF in the expression of transiently transfected versus stably integrated HTLV-1 LTR. Furthermore, with dominant-negative mutants of CREB, p300, and P/CAF, we found that activation of integrated HTLV-1 LTR by an ambient stress signal, UV-C, proceeds through a path mechanistically distinct from that used by viral oncoprotein, Tax. Our findings point to additional complexities in the regulated expression of HTLV-1 proviruses compared with those hitherto revealed through transfection studies.

Documentos Relacionados

• Response of the human T-cell leukemia virus type 1 long terminal repeat to cyclic AMP.
• Nucleotide sequence analysis of the long terminal repeat of human T-cell leukemia virus type II.
• Functional activation of the long terminal repeat of human T-cell leukemia virus type I by a trans-acting factor.
• Human immunodeficiency virus long terminal repeat responds to T-cell activation signals.
• Repetitive structure in the long-terminal-repeat element of a type II human T-cell leukemia virus.